GSK, Immunocore enter deal worth up to $508M

07/10/2013 | Reuters · Genetic Engineering & Biotechnology News

GlaxoSmithKline and Immunocore agreed to collaborate in the discovery and development of drugs using the latter's ImmTACs technology. Immunocore will handle preclinical development and initial clinical studies while GSK will assume the remaining development and commercialization. GSK could pay Immunocore up to about $211 million in preclinical milestone fees and as much as about $297 million in development and commercial milestone payments plus sales royalties. Last month, Genentech and Immunocore formed a similar partnership.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN